Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000-2020.
Tankwanchi, AS; Jaca, A; Ndlambe, AM; Zantsi, ZP; Bowman, B; Garrison, MM; LARSON, HJ; Vermund, SH; Wiysonge, CS;
2022
Expert review of vaccines, (2022).21 9 10.1080/14760584.2022.2084075.
COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery.
Toor, J; Li, X; JIT, M; Trotter, C; Echeverria-Londono, S; Hartner, A-M; Roth, J; Portnoy, A; Abbas, K; Ferguson, N; Gaythorpe, KA M;
2022
medRxiv (2022). 10.1101/2022.01.07.22268891.
Solidarity COVID-19 vaccine trial.
WATSON-JONES, D;
2022
(2022).
End-point definition and trial design to advance tuberculosis vaccine development.
Garcia-Basteiro, AL; WHITE, RG; Tait, D; Schmidt, AC; Rangaka, MX; Quaife, M; Nemes, E; Mogg, R; Hill, PC; Harris, RC; Hanekom, WA; Frick, M; Fiore-Gartland, A; Evans, T; Dagnew, AF; Churchyard, G; Cobelens, F; Behr, MA; Hatherill, M;
2022
European respiratory review, (2022).31 164 10.1183/16000617.0044-2022.
Review of Existing Evidence on Single Dose Vaccination.
WATSON-JONES, D;
2022
(2022).
Immunogenicity and immunobridging of single dose HPV vaccine in Tanzanian girls – the DoRIS trial.
WATSON-JONES, D;
2022
(2022).
Immune Response of a Two-dose, Heterologous Ebola Vaccine Regimen Using a 'One Assay, One Lab' Approach: Summary of Three African Clinical Trials.
WATSON-JONES, D;
2022
(2022).
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries.
Portnoy, A; Arcand, J-L; CLARK, R; WEERASURIYA, C; Mukandavire, C; Bakker, R; Patouillard, E; Gebreselassie, N; Zignol, M; JIT, M; WHITE, R; Menzies, N;
2022
medRxiv (2022). 10.1101/2022.11.23.22282690.
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.
Wagstaffe, HR; Anzala, O; Kibuuka, H; ANYWAINE, Z; Sirima, SB; Thiébaut, R; Richert, L; Levy, Y; Lacabaratz, C; Bockstal, V; Luhn, K; Douoguih, M; GOODIER, MR;
2022
Vaccines, (2022).10 6 10.3390/vaccines10060884.
Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li, X; Bilcke, J; Vázquez Fernández, L; Bont, L; Willem, L; Wisløff, T; JIT, M; Beutels, P; REspiratory Syncytial virus Consortium in EUrope (,;
2022
The Journal of infectious diseases, (2022).226 Suppl 1 10.1093/infdis/jiac064.